Technion Assistant Professor Avi Schroeder

Israeli researchers create tiny “barcodes” that bring promise for personal drug therapies

Haifa, Israel

Using synthetic DNA sequences as the tiniest of barcodes, Technion-Israel Institute of Technology researchers have developed a new diagnostic technology for determining the suitability of specific anticancer drugs to a specific patient — before treatment even begins.

The study, published in Nature Communications, was led by Assistant Professor Avi Schroeder of the Technion Faculty of Chemical Engineering and the Technion Integrated Cancer Center.

Technion Assistant Professor Avi Schroeder

   “The medical world is now moving toward personalized medicine, but treatments tailored only according to the patient’s genetic characteristics don’t always grant an accurate prediction of which medicine will be best for each patient,” Schroeder says. “We, however, have developed a technology that complements this field.”

Together with doctoral student Zvi Yaari and other researchers, Schroeder created what amounts to a safe, miniature lab in each patient’s body, which examines the effectiveness of a specific drug in that individual patient.

The researchers packed miniscule quantities of anticancer drugs inside of dedicated nanoparticles they developed. The unique design of the anticancer drug-loaded nanoscale packages gives them the ability to flow in the bloodstream to the tumor, where they are swallowed by the cancer cells.

Technion doctoral student Zvi Yaari

Synthetic DNA sequences attached to the anticancer drugs in advance serve as barcode readers of each drug’s activity in the cancer cells.
After 48 hours, a biopsy is taken from the tumor and the barcode analysis provides accurate information about the cells that were (or were not) destroyed by each drug. In essence, the system monitors the effect of each drug on the patient’s tumor cells. The researchers are currently working with drugs registered as anti-cancer drugs, but, in principle, they can test a battery of drugs for each patient to find the most effective.
    “It’s a bit like testing for allergies, where simple tests provide us with a specific person’s allergy profile,” Schroeder says. “Here we developed a simple test that provides us with a profile of the patient’s response to the designated drug. This method makes it possible to test the effectiveness of several drugs concurrently in the patient’s tumor, in minute doses not felt by the patient and which do not pose any danger to him or her. Based on the test results, the most effective drug for the specific patient is selected.”
    The study, based on experiments in mice, focused on the effect of various drugs on Triple Negative type breast cancer — a particularly challenging cancer that does not respond well to standard treatment and presents difficulties for doctors to match the drug to the patient.

To make sure the experiment does indeed examine the effect of the drug itself, and not the possible effect of the nanoscale package, “placebo packages” that did not contain drugs were also inserted into tumors. The result: The anticancer drugs were found at the end of the process mainly in dead cancer cells — they had killed them — while the placebo packages were found mainly in live tumor cells. A comparison between the various anticancer drugs also found differences in the effectiveness of the various drugs.
    “This technology provides a new window into fundamental insights about the mechanisms of cancer and resistance to various drugs,” Schroeder says, “but my thoughts are also practical: how our research could help people. Therefore, I am thrilled by the current success. It will take a lot more work to turn our development into a product available to the public, but I believe we’ll see it at the clinic within a few years.”
    The study is being funded by a prestigious H2020-ERC grant from the European Union and by the Israel Science Foundation and the Israel Cancer Association. The new technology was patented, and now there are discussions regarding its commercialization.       
    Miri Ziv, Israel Cancer Association director-general, says, “We are proud to have supported such important and promising research that could provide a customized solution for patients and lead to more efficient, precise and accurate treatment.”